Current Controversies in Neoadjuvant Therapy for Pancreatic Cancer

Erin P Ward; Herbert J Zeh Iii; Susan Tsai

doi:10.1016/j.soc.2021.06.010

Current Controversies in Neoadjuvant Therapy for Pancreatic Cancer

Surg Oncol Clin N Am. 2021 Oct;30(4):657-671. doi: 10.1016/j.soc.2021.06.010.

Authors

Erin P Ward¹, Herbert J Zeh Iii², Susan Tsai³

Affiliations

¹ Surgical Oncology Division, Department of Surgery, Medical College of Wisconsin, 8701 W Watertown Plank Road, Milwaukee, WI 53226, USA.
² Division of Surgical Oncology, Department of Surgery, UT Southwestern (University of Texas), 5323 Harry Hines Blvd. Dallas, TX 75390, USA.
³ Surgical Oncology Division, Department of Surgery, Medical College of Wisconsin, 8701 W Watertown Plank Road, Milwaukee, WI 53226, USA. Electronic address: stsai@mcw.edu.

PMID: 34511188
DOI: 10.1016/j.soc.2021.06.010

Abstract

Over the last two decades, there have been significant changes in the management of patients with localized pancreatic cancer. The rationale for an evolution toward a neoadjuvant approach and summary of relevant clinical trials is reviewed. Controversies in identifying optimal neoadjuvant therapeutic approaches are discussed.

Keywords: CA19-9; Micro-metastatic disease; Neoadjuvant therapy; Pancreatic cancer.

Publication types

Review

MeSH terms

Humans
Neoadjuvant Therapy*
Pancreatic Neoplasms* / drug therapy